Celldex fleshes out case for Xolair challenger in chronic hives
Celldex Therapeutics is detailing more data from a Phase I trial, close to eight months after sharing initial responses from an interim analysis.
The New Jersey biotech rolled out the results at the American Academy of Allergy, Asthma & Immunology (AAAAI) meeting in San Antonio on Sunday, saying that it saw a 56% complete response rate after 12 weeks in a Phase Ib trial testing barzolvolimab (formerly CDX-0159) in patients with moderate to severe chronic spontaneous urticaria (CSU) and not responding to antihistamines.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.